Drug interactions avoided - A useful indicator of good prescribing practice

British Journal of Clinical Pharmacology

Volumn 49, Issue 4, 2000, Pages 369-372

  Williams, D ^a   Kelly, A ^a   Feely, J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

General medical services; Ireland; Odds ratio; Quality prescribing

Indexed keywords

CIMETIDINE; FAMOTIDINE; NIZATIDINE; PHENYTOIN; RANITIDINE; THEOPHYLLINE; WARFARIN;

ARTICLE; DRUG INTERACTION; GENERAL PRACTICE; GOOD CLINICAL PRACTICE; HEALTH CARE QUALITY; HUMAN; IRELAND; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL;

ANTICOAGULANTS; ANTICONVULSANTS; CIMETIDINE; DRUG INTERACTIONS; HISTAMINE H2 ANTAGONISTS; HUMANS; IRELAND; ODDS RATIO; PHENYTOIN; PRESCRIPTIONS, DRUG; THEOPHYLLINE; VASODILATOR AGENTS; WARFARIN;

EID: 0034033411     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00177.x     Document Type: Article

References (22)

1. 1 Lawrence M, Olesen F. Indicators of quality in health care. Eur J Gen Pract 1997; 3: 103-108.
2. 2 Batman DN, Eccles M, Campbell M, Soutter J, Roberts SJ, Smith JM. Setting standards of prescribing performance in primary care: Use of a consensus group of general practitioners and application of standards to practices in the north of England. Br J Gen Pract 1996; 40: 20-25.
3. 3 Thomas S, Campbell M. Utilization of appetite suppressants in England: a putative indicator of poor prescribing practice. Pharmacoepidemiol Drug Safety 1996; 5: 237-246.
4. 4 Buetow S, Sibbald B, Cantrill J, Halliwell S. Prevalence of potentially inappropriate long term prescribing in general practice in the United Kingdom 1980-95: systematic literature review. Br Med J; 1996; 313: 1371-1374.
5. 5 Bates DW, Cullen D, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA 1995; 274: 29-34.
6. 6 Classen D, Pestonik S, Evans S, Lloyd J, Burke J. Adverse drug events in hospitalised patients excess length of stay, extra costs, and attributable mortality. JAMA 1997; 227: 301-306.
7. 7 Bates D, Spell N, Cullen D, Burdick E, Leape L. Costs of adverse drug events in hospitalised patients. JAMA 1997; 277: 307-311.
8. 8 Johnson Z, Dack P. Prescribing patterns for combinations of Warfarin and potentially dangerous interacting drugs in a large general practice population. Pharmacoepidemiol Drug Safety 1992; 1: 119-123.
9. 9 Hansten PD. Drug interactions with antisecretory drugs. Aliment Pharmacol Ther 1991; 5(Suppl 1): 121-128.
10. 10 Feely J. The influence of pharmacoeconomic factors on prescribing patterns in Ireland. Pharmacoeconomics 1992; 2: 99-106.
11. 11 Feely J, Chan R, McManus J, O'Shea B. The influence of hospital-based prescribers on prescribing in general practice. Pharmacoeconomics 1999; August 16: 175-181.
12. 12 General Medical Services (Payments) Board. Financial and Statistical Analysis of Claims and Payments 1998.
13. 13 Audit Commission. A Prescription for Improvement; Towards More Rational Prescribing in General Practice. London, HMSO, 1994; 26-27.
14. 14 McColl A, Roderick P, Gabbay J, Smith H, Moore M. Performance indicators for primary care groups: an evidence-based approach. Br Med J 1998; 317: 1354-1360.
15. 15 NHS executive. The New NHS, Modern and Dependable: a National Framework for Assessing Performance. London: Department of Health 1998.
16. 16 Majeed FA, Voss S. Performance indicators for general practice. Br Med J 1995; 311: 209-210.
17. 17 Campbell SM, Roland MO, Qualyle JA, Shekelle PG, Buetow S. Quality indicators for general practice; which ones can general practitioners and health authority managers agree are important and how useful are they? J Public Health Med 1998; 20: 414-;442.
18. 18 Oborne A, Batty G, Maskrey V, Swift C, Jackson S. Development of prescribing indicators for elderly medical inpatients. Br J Clin Pharmacol 1997; 43: 91-97.
19. 19 Suissa S. Relative excess risk: an alternative measure of comparative risk. Am J Epidemiol 1999; 150: 279-282.
20. 20 Shinn AF. Clinical relevance of cimetidine drug interactions. Drug Safety 1992; 7: 245-267.
21. 21 Bartle WR, Walker SE, Shapero T. Dose dependent effect of cimetidine on phenytoin pharmacokinetics. Clin Pharmacol Ther 1983; 33: 649-655.
22. 22 Grygiel JJ, Miners JO, Drew R, et al. Differential effects of cimetidine on theophylline metabolic pathways. Eur J Clin Pharmacol 1984; 26: 335.